JP2015530087A5 - - Google Patents

Download PDF

Info

Publication number
JP2015530087A5
JP2015530087A5 JP2015529031A JP2015529031A JP2015530087A5 JP 2015530087 A5 JP2015530087 A5 JP 2015530087A5 JP 2015529031 A JP2015529031 A JP 2015529031A JP 2015529031 A JP2015529031 A JP 2015529031A JP 2015530087 A5 JP2015530087 A5 JP 2015530087A5
Authority
JP
Japan
Prior art keywords
species
human
immune library
target antigen
antibody molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015529031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015530087A (ja
JP6391574B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/067979 external-priority patent/WO2014033252A1/en
Publication of JP2015530087A publication Critical patent/JP2015530087A/ja
Publication of JP2015530087A5 publication Critical patent/JP2015530087A5/ja
Application granted granted Critical
Publication of JP6391574B2 publication Critical patent/JP6391574B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015529031A 2012-08-31 2013-08-30 種間標的内交差反応性を有する抗体分子を産生する方法 Active JP6391574B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695664P 2012-08-31 2012-08-31
US61/695,664 2012-08-31
PCT/EP2013/067979 WO2014033252A1 (en) 2012-08-31 2013-08-30 Method for producing antibody molecules having inter-species, intra-target cross-reactivity

Publications (3)

Publication Number Publication Date
JP2015530087A JP2015530087A (ja) 2015-10-15
JP2015530087A5 true JP2015530087A5 (enExample) 2017-09-21
JP6391574B2 JP6391574B2 (ja) 2018-09-26

Family

ID=49080903

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529031A Active JP6391574B2 (ja) 2012-08-31 2013-08-30 種間標的内交差反応性を有する抗体分子を産生する方法

Country Status (10)

Country Link
US (1) US20150203840A1 (enExample)
EP (2) EP2890711B1 (enExample)
JP (1) JP6391574B2 (enExample)
CN (1) CN104583238A (enExample)
AU (2) AU2013310924B2 (enExample)
CA (1) CA2878712A1 (enExample)
DK (1) DK2890711T3 (enExample)
IL (1) IL236523B (enExample)
IN (1) IN2015DN00140A (enExample)
WO (1) WO2014033252A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2828753C (en) 2011-03-16 2022-07-26 arGEN-X BV Antibodies to cd70
EP3786187A1 (en) 2013-08-01 2021-03-03 Université catholique de Louvain Antibody binding a complex of human glycoprotein a repetitions predominant (garp) and latent tgf-beta-1
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
CA3030099A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
BR112020008514A2 (pt) 2017-10-31 2020-10-20 Staten Biotechnology B.V. anticorpos anti-apoc3 e métodos de uso dos mesmos
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
CN111712258B (zh) 2017-12-12 2024-03-15 开拓免疫医疗公司 抗trem2抗体和相关方法
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2019151865A1 (en) 2018-02-05 2019-08-08 Stichting Vu Inverse agonistic anti-us28 antibodies
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
EP4277706A1 (en) 2021-01-15 2023-11-22 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
EP4612180A1 (en) 2022-10-31 2025-09-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
WO2024101989A1 (en) 2022-11-08 2024-05-16 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
EP4631501A1 (en) 2024-04-09 2025-10-15 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Combinations of a calcium homeostasis disruptor with a death receptor 5 agonist for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4460155B2 (ja) * 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
EP3299393A1 (en) * 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN1735629B (zh) * 2002-11-08 2012-05-09 埃博灵克斯股份有限公司 针对肿瘤坏死因子-α的单结构域抗体及其用途
MXPA05010134A (es) * 2003-03-24 2005-11-16 Zymogenetics Inc Anticuerpos anti-il-20, metodos y moleculas de enlace que se usan en la inflamacion.
CN1845937A (zh) * 2003-03-24 2006-10-11 津莫吉尼蒂克斯公司 抗il－20抗体和结合伴侣以及在炎症中的使用方法
CN101228188A (zh) * 2005-06-21 2008-07-23 佐马技术有限公司 IL-1β结合抗体及其片段
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
JP6184695B2 (ja) * 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
GB201002238D0 (en) * 2010-02-10 2010-03-31 Affitech As Antibodies
MX385858B (es) * 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.

Similar Documents

Publication Publication Date Title
JP2015530087A5 (enExample)
CN103562403A8 (zh) 识别肿瘤起始细胞的抗体和抗原及其应用
AR108800A1 (es) Purificación de anticuerpos multiespecíficos
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
EA201791270A1 (ru) Модифицированные april-связывающие антитела
JP2012031178A5 (enExample)
MY189159A (en) Multispecific antigen-binding molecules and uses thereof
MX395317B (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
EA201400875A1 (ru) Антитела к cd47 и способы их применения
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
MX2016003593A (es) Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
EA201690182A1 (ru) АНТИТЕЛА ПРОТИВ ФАКТОРА КОМПЛЕМЕНТА C1q И ИХ ПРИМЕНЕНИЯ
EA201791393A3 (ru) Антитела к erbb3 и их применение
EA201492137A1 (ru) Антитела к cd33 и их применение в лечении рака
MX369220B (es) Moleculas que enlazan cd3 capaces de enlazar a cd3 humano y no humano.
EA201790438A1 (ru) Антигенсвязывающие белки, которые связываются с cxcr5
EP3421488A3 (en) Multispecific antigen-binding molecules and uses thereof
AU2013310924A8 (en) Method for producing antibody molecules having inter-species, intra-target cross-reactivity
WO2015127134A3 (en) Complement component c5 antibodies
HK1218550A1 (zh) 常見輕鏈小鼠
GT201300149A (es) Proteinas de union al tnf-a
WO2015028454A3 (en) Method for the treatment of fibrotic disease
JP2015530399A5 (enExample)
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения